What Does a Mass on Your Liver Mean?

Most liver masses are benign and require no treatment. The widespread use of abdominal imaging for unrelated complaints has led to a surge in incidentally discovered liver lesions, and the vast majority turn out to be harmless fluid-filled cysts or non-cancerous growths like hemangiomas. That said, some liver masses are malignant, either originating in the liver itself or arriving there as metastases from cancer elsewhere in the body. The difference between a harmless finding and a serious one depends on your medical history, the characteristics of the mass on imaging, and sometimes blood work or biopsy results.

Why Liver Masses Are Found So Often Now

A generation ago, many liver masses went undetected for an entire lifetime because there was no reason to look. Today, CT scans, MRIs, and ultrasounds ordered for abdominal pain, gallbladder trouble, or even routine checkups frequently reveal liver findings that were never causing symptoms. Benign liver lesions are increasingly diagnosed in daily practice precisely because of this growing use of imaging in patients who have non-specific symptoms and no elevated risk of liver cancer.¹ The result is a common and understandable scenario: you go in for something unrelated, and someone mentions a “mass” or “lesion” on your liver. The word “mass” sounds alarming, but in medical imaging it simply means an area that looks different from the surrounding tissue. It does not imply cancer.

The Most Common Benign Liver Masses

Several types of non-cancerous growths account for the bulk of incidentally found liver masses. Understanding which one you have matters because management differs between them, even though none of them are cancer.

Hemangiomas

Hepatic hemangioma is the single most common benign liver tumor. These are tangles of blood vessels that form during development, and they are almost always found by accident during imaging done for another reason.² Most hemangiomas are small, cause no symptoms, and never need treatment. Occasionally a very large one can cause discomfort or, rarely, bleeding, but for the overwhelming majority of people, the right response is simply knowing it is there and leaving it alone. Hemangiomas have a distinctive appearance on contrast-enhanced imaging, so radiologists can usually identify them without a biopsy.

Focal Nodular Hyperplasia

Focal nodular hyperplasia (FNH) is the second most common benign liver tumor. It is a cluster of normal-looking liver cells organized around a central scar, and it occurs most often in women of childbearing age. FNH has essentially no risk of turning into cancer and almost never bleeds or ruptures. On imaging with a liver-specific contrast agent, FNH tends to appear bright or the same intensity as the surrounding liver on delayed images, which helps distinguish it from other masses.³ Because FNH is harmless, the main clinical task is making sure it is not something else.

Hepatic Adenomas

Hepatic adenomas are less common and more clinically relevant. Unlike FNH, adenomas carry a small but real risk of bleeding and, in certain subtypes, malignant transformation. This is why telling the two apart matters so much: FNH can be left alone with confidence, but adenomas sometimes need to be removed or carefully monitored.⁴ Adenomas are linked to oral contraceptive use, anabolic steroid use, and certain metabolic conditions. On liver-specific MRI, adenomas tend to appear darker than the surrounding liver on delayed images, which is the opposite of what FNH typically does.³ Larger adenomas and those occurring in men are at higher risk for complications.

Simple Cysts

Simple liver cysts are fluid-filled sacs lined with a thin wall. They are extremely common, present in a significant percentage of the population, and almost never cause problems. On ultrasound they look like dark, well-defined bubbles, and the diagnosis is straightforward. The only time cysts become medically interesting is when they are very large, when they have internal features that make them look complex, or when they might be something other than a simple cyst, such as a parasitic (hydatid) cyst or an abscess.⁵ In regions where certain parasitic infections are endemic, a cyst-like liver mass warrants extra scrutiny.

When a Liver Mass Might Be Cancer

While most liver masses are benign, the possibility of malignancy is the reason doctors take these findings seriously, especially in people with known risk factors. Liver cancers fall into two broad categories: cancers that start in the liver and cancers that spread to the liver from somewhere else.

Primary Liver Cancers

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. It arises from the liver cells themselves and is strongly associated with chronic liver disease. Cirrhosis, regardless of its cause, is the single biggest risk factor. Hepatitis C infection carries the highest HCC incidence among people with cirrhosis, with five-year cumulative rates around 17% in Western populations and 30% in Japan. In hepatitis B-related cirrhosis, the five-year risk is roughly 10–15% depending on the region. Even without viral hepatitis, alcoholic cirrhosis carries about an 8% five-year cumulative risk.⁶ Additional factors like older age, male sex, smoking, alcohol use, and metabolic conditions such as obesity and diabetes further raise the risk in people who already have viral hepatitis.⁷

Intrahepatic cholangiocarcinoma, a cancer of the bile ducts within the liver, is the other major primary liver malignancy. It is less common than HCC but can be difficult to distinguish from it on imaging because their appearances sometimes overlap.⁸ There are also rare combined tumors that share features of both. The distinction matters because treatment strategies differ.

Metastatic Liver Disease

The liver is one of the most common sites for cancer to spread to, thanks to its rich blood supply and the fact that blood from the entire gastrointestinal tract passes through it. When cancer cells from a primary tumor elsewhere break free and travel through the bloodstream, they frequently land in the liver. In a large study of over 23,000 patients with confirmed liver metastases, about 92% were carcinomas, with adenocarcinoma being the most frequent subtype at around 75%. The most common primary sites were colorectal cancer, pancreatic cancer, and breast cancer.⁹ Other tumor types, including lymphomas, sarcomas, and melanomas, can also metastasize to the liver.¹⁰

The pattern of where liver metastases come from varies with age and sex. In women under 50, breast cancer is the more common source of metastatic adenocarcinoma in the liver. In women over 70 and in older men, gastrointestinal tumors and squamous cell lung carcinoma become more frequent origins.⁹ Sometimes the liver mass is the first sign that cancer exists elsewhere in the body, and tracking down the primary site requires specialized tissue staining and imaging.

How Doctors Figure Out What a Liver Mass Is

The diagnostic process typically starts with imaging and may include blood tests and, less commonly, a tissue sample. The goal is to characterize the mass well enough to decide whether it needs treatment, monitoring, or nothing at all.

Imaging

Ultrasound is usually the first tool, both because it is inexpensive and widely available and because it is the standard screening method for people at high risk. However, ultrasound has real limitations. Its sensitivity for detecting HCC ranges widely, from around 40% to 81%, depending on the patient’s body size, the severity of underlying liver disease, and the skill of the operator. In patients with cirrhosis, the combined sensitivity for early-stage HCC drops to roughly 47%, partly because the scarring and nodularity of a cirrhotic liver can mask small tumors.¹¹ About 18% of cirrhosis patients have limited ultrasound visualization at baseline, often because of a heterogeneous liver texture or body habitus that makes imaging difficult.¹²

When regular ultrasound is inconclusive, contrast-enhanced ultrasound (CEUS) can substantially improve accuracy. One study found that CEUS detected malignant lesions at a rate of 75%, compared with about 43% for conventional ultrasound, and it performed even better for very small lesions under 1 cm.¹³ CT and MRI remain the workhorses for definitive characterization. Multiphasic contrast-enhanced CT and MRI capture how a mass behaves as contrast flows through it in different phases, which gives radiologists strong clues about the mass type.¹⁴ For patients with cirrhosis who have poor ultrasound visualization, MRI performs better than ultrasound for detecting HCC.¹⁵

Blood Tests

Alpha-fetoprotein (AFP) is the best-known blood marker for liver cancer, but it is far from perfect as a standalone test. When used alone to diagnose primary liver cancer, AFP has a sensitivity of roughly 63–85% and a specificity of about 80%, meaning it misses a meaningful number of cancers and occasionally flags benign conditions.¹⁶ AFP levels can be elevated in pregnancy, certain non-cancerous liver diseases, and some non-liver cancers. A more refined version of the test, called AFP-L3, measures a specific fraction of AFP that is more closely tied to HCC. One study found AFP-L3 achieved 90% sensitivity and 100% specificity for distinguishing HCC from cirrhosis, outperforming standard AFP.¹⁷ Combining AFP with other markers like CA19-9 and CEA can also improve diagnostic accuracy compared with any single marker, though no combination is flawless.¹⁶

Things That Look Like Masses but Are Not

One underappreciated source of anxiety is the pseudolesion: an imaging finding that mimics a liver mass but is not actually a growth of any kind. The liver has an unusual dual blood supply, receiving blood from both the hepatic artery and the portal vein, and this creates opportunities for localized differences in blood flow to show up on contrast-enhanced scans as apparent “lesions.”¹⁸ Focal fatty deposits, areas where fat is conspicuously absent, confluent scarring, and transient differences in how contrast washes through the liver can all create spots that an inexperienced eye might flag as tumors.

These pseudolesions are being encountered more frequently as CT and MRI technology improves, because higher-resolution scans reveal subtler variations in the liver tissue. Some can even cause tissue-level changes such as localized fat accumulation or focal hyperplasia, which further complicates the picture.¹⁹ The practical takeaway is that not every “spot” on your liver scan represents an actual mass. An experienced radiologist familiar with these artifacts can usually distinguish them from real lesions, but if there is any uncertainty, follow-up imaging with a different technique often resolves the question.

Treatment Options When a Mass Needs Intervention

For benign masses, the answer is often “do nothing.” Hemangiomas, FNH, and simple cysts rarely require treatment. Hepatic adenomas may need surgical removal if they are large, growing, or found in a male patient, because of the risk of bleeding or cancerous change. For malignant masses, treatment depends heavily on the type of cancer, its stage, the health of the underlying liver, and the patient’s overall condition.

Surgery and Transplantation

Surgical removal of the tumor (resection) is the goal when the cancer is caught early and the remaining liver is healthy enough to function well afterward. For HCC specifically, liver transplantation offers excellent results in selected candidates, effectively curing both the cancer and the underlying cirrhosis that gave rise to it. Selection has traditionally been based on the size and number of tumors, which serve as rough indicators of how aggressively the cancer is behaving.²⁰ Newer techniques aim to identify which patients are truly at low risk for recurrence, even if their tumors exceed traditional size limits.

Locoregional Therapies

For liver cancers that cannot be surgically removed, several procedures can target tumors directly without cutting them out. Transarterial chemoembolization (TACE) delivers chemotherapy drugs directly into the artery feeding the tumor while simultaneously blocking that artery, starving the tumor of blood. It is considered a first-line treatment for intermediate-stage HCC.²¹ Thermal ablation uses heat (radiofrequency or microwave energy) to destroy tumor cells. The two approaches are often combined, and pooled results suggest the combination outperforms either one alone, particularly for tumors larger than 3 cm that are not surgical candidates.²² In one study, combining drug-eluting bead TACE with radiofrequency ablation produced a complete response rate of about 79%, compared with 34% for bead TACE alone, and patients in the combination group lived longer overall.²³

Systemic Therapy

When liver cancer is advanced or has spread beyond the liver, systemic drug therapy becomes the primary option. The landscape has shifted in recent years with the introduction of immunotherapy combinations. In 2020, the combination of atezolizumab (an immune checkpoint inhibitor) and bevacizumab (which targets blood vessel growth) was approved worldwide for advanced HCC. In the pivotal trial, roughly 30% of patients achieved an objective response, with about 8% reaching a complete response.²⁴ This combination outperformed the previous standard of care and has become the new first-line treatment for unresectable HCC.

HCC Without Cirrhosis and the Rise of Fatty Liver Disease

Traditionally, liver cancer screening has been aimed at people with cirrhosis or chronic hepatitis. But there is a growing recognition that HCC can develop in people with non-alcoholic fatty liver disease (NAFLD) or its more severe form (NASH) even in the absence of cirrhosis. Case series have documented HCC arising in patients whose only major risk factors were obesity, diabetes, or metabolic syndrome, with no evidence of cirrhotic scarring in the liver.²⁵ This is concerning because these patients fall outside current screening guidelines, meaning their cancers are more likely to be found late, when options are limited. As obesity and metabolic syndrome continue to rise globally, this pattern is expected to become more common. It raises difficult questions about who should be screened and how.

Ongoing Surveillance for High-Risk Patients

If you have cirrhosis, guidelines recommend regular ultrasound surveillance, usually every six months, to catch HCC early. But surveillance is not perfect. In one study of cirrhosis patients followed for a median of about four and a half years, roughly 14% developed HCC. The risk was not evenly distributed. Patients whose ultrasound showed a coarse large nodular pattern had the highest risk, with about 41% developing HCC during follow-up, while those with a homogeneous or bright liver pattern did not develop HCC at all during the study period.²⁶ This kind of risk stratification could someday help tailor how often individual patients need screening.

An important question for people with hepatitis C who have been successfully treated is whether surveillance can stop. Even after achieving a sustained virological response (meaning the virus is no longer detectable), the risk of HCC does not drop to zero, particularly in those who had advanced fibrosis or cirrhosis before treatment. International guidelines recommend continuing surveillance in these patients regardless of whether their liver scarring appears to improve after antiviral therapy.²⁷

Liver Masses in Children

Liver masses in children are a very different clinical picture from those in adults. The most common malignant liver tumor in young children is hepatoblastoma, a rare cancer with roughly 100 cases reported per year in the United States.²⁸ It typically affects children under the age of three. Unlike adult liver cancers, which are strongly linked to chronic liver disease, hepatoblastoma arises in otherwise healthy livers, and the risk factors are not well understood.

The good news is that outcomes have improved substantially over the decades. Treatment typically involves chemotherapy to shrink the tumor followed by surgical removal, and in some cases liver transplantation. In the German cooperative studies, overall survival improved from 75% in the late 1980s cohort to 89% in the most recent group.²⁹ In the Japanese study group’s experience, the five-year overall survival was about 83% across 331 patients, though outcomes for high-risk cases with extensive disease or metastases remained poor.³⁰ Chemotherapy has proven particularly valuable for converting previously unresectable tumors into ones that can be surgically removed.

AI and Radiomics in Liver Imaging

One area evolving rapidly is the use of artificial intelligence and radiomics, a technique that extracts large numbers of quantitative features from medical images, to improve the detection and characterization of liver masses. These tools have shown promising results for detecting HCC, characterizing liver lesions, and automating the process of measuring tumor size and boundaries.³¹ One particularly tricky clinical problem is distinguishing between HCC, intrahepatic cholangiocarcinoma, and combined tumors on imaging, since their appearances overlap. Researchers are now developing machine-learning models trained on multiphasic CT data to classify these three tumor types simultaneously, something that remains challenging even for experienced radiologists.⁸ These tools are not yet replacing human judgment, but they may eventually serve as a second opinion built into the imaging software, flagging suspicious features that a busy reader might miss or helping standardize diagnoses across institutions with varying levels of radiological expertise.³²

1
PubMed. Benign liver lesions 2022: Guideline for clinical practice
2
PubMed Central. Hepatic hemangioma: What internists need to know
3
PubMed Central. Characterization of Hepatic Adenoma and Focal Nodular Hyperplasia with Gadoxetic Acid
4
PubMed. Focal Nodular Hyperplasia and Focal Nodular Hyperplasia-like Lesions
5
PubMed Central. Liver Hydatid Cyst Masquerading as a Liver Abscess
6
PubMed. Hepatocellular carcinoma in cirrhosis: incidence and risk factors
7
PubMed Central. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma
8
PubMed. Three-class radiomic differentiation of hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma on multiphasic contrast-enhanced CT
9
PubMed Central. Incidence and origin of histologically confirmed liver metastases: an explorative case-study of 23,154 patients
10
PubMed. A practical approach to liver metastasis from unknown primary cancer: What surgeons need to know
11
PubMed Central. Ultrasonography of Hepatocellular Carcinoma: From Diagnosis to Prognosis
12
Clinical Gastroenterology and Hepatology. Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis
13
PubMed Central. Enhanced diagnostic accuracy of contrast-enhanced ultrasound in liver space-occupying lesions
14
PubMed Central. STD-Net: a spatio-temporal decoupling network for multiphasic liver lesion segmentation and characterization
15
Liver Cancer International. Liver ultrasound in cirrhosis is inadequate for hepatocellular carcinoma surveillance compared to magnetic resonance imaging
16
PubMed Central. Serum Biomarkers AFP, CEA and CA19-9 Combined Detection for Early Diagnosis of Hepatocellular Carcinoma
17
International Journal of Pathology. Diagnostic value of alpha-fetoprotein and lens culinaris agglutinin-reactive Alpha-fetoprotein in liver cirrhosis and hepatocellular carcinoma patients in Pakistan
18
PubMed Central. Hepatic pseudolesions caused by alterations in intrahepatic hemodynamics
19
Clinical Imaging. Unveiling the unreal: Comprehensive imaging review of hepatic pseudolesions
20
PubMed. Transplantation for hepatocellular carcinoma: The Milan criteria and beyond
21
PubMed Central. Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?
22
PubMed. Thermal ablation combined with transarterial chemoembolization for hepatocellular carcinoma
23
PubMed Central. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients
24
PubMed Central. Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy
25
PubMed. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience
26
PubMed Central. Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns
27
PubMed. Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?
28
PubMed Central. A Case Report and a Review of Pediatric Hepatoblastoma
29
PubMed. Treatment of hepatoblastoma in the German cooperative pediatric liver tumor studies
30
PubMed. A cisplatin plus pirarubicin-based JPLT2 chemotherapy for hepatoblastoma
31
PubMed Central. The Role of Radiomics and AI Technologies in the Segmentation, Detection, and Management of Hepatocellular Carcinoma
32
PubMed. Artificial intelligence: A review of current applications in hepatocellular carcinoma imaging